prazosin has been researched along with Central Nervous System Demyelinating Diseases, Hereditary in 1 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortés, MD | 1 |
| Arias-Montaño, JA | 1 |
| Eguibar, JR | 1 |
1 other study available for prazosin and Central Nervous System Demyelinating Diseases, Hereditary
| Article | Year |
|---|---|
Prazosin increases immobility episodes in taiep rats without changes in the properties of alpha1 receptors.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Binding, Competitive | 2007 |